<DOC>
	<DOCNO>NCT01114191</DOCNO>
	<brief_summary>This phase 1 , open-label study design determine interaction ketoconazole ABT-869 .</brief_summary>
	<brief_title>A Study Assess Effect Ketoconazole Pharmacokinetics Linifanib ( ABT-869 )</brief_title>
	<detailed_description>This study design explore drug interaction ketoconazole ABT-869 determine potential effect ketoconazole metabolism ABT-869 . ABT-869 take alone combination ketoconazole . The safety single dose administration ABT-869 administer alone combination ketoconazole assess .</detailed_description>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Inclusion Criteria 1 . Male female age &gt; = 18 year . 2 . Must histologically cytologically confirm nonhematologic malignancy . 3 . Eastern Cooperative Oncology Group ( ECOG ) Performance Score 02 . 4 . Must adequate bone marrow , renal hepatic function follow : Bone Marrow : Absolute neutrophil count ( ANC ) &gt; = 1,500/mm3 ; Platelets &gt; = 100,000/mm3 ; Hemoglobin &gt; = 9.0 g/dL Renal function : serum creatinine &lt; = 2.0 mg/dL ; Hepatic function : AST ALT &lt; = 1.5 x ULN unless liver metastasis present , AST ALT &lt; = 5.0 x ULN ; bilirubin &lt; = 1.5 mg/dL 5 . Must PTT &lt; = 1.5 x ULN and/or INR &lt; = 1.5 . 6 . Women childbearing potential men must agree use adequate contraception ( one follow list ) prior study entry , duration study participation 90 day follow completion therapy . Women childbearing potential must negative urine pregnancy test within 7 day prior initiation treatment and/or post menopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Total abstinence sexual intercourse ( minimum one complete menstrual cycle ) ; Vasectomized male subject vasectomized partner female subject ; Hormonal contraceptive ( oral , parenteral transdermal ) least 3 month prior study drug administration ; subject currently use hormonal contraceptive , also use barrier method study 1 month study completion ; Intrauterine device ( IUD ) ; Double barrier method ( condom , contraceptive sponge , diaphragm vaginal ring spermicidal jelly cream ) ; Additionally , male subject ( include vasectomize ) whose partner pregnant might pregnant must agree use condom duration study 90 day follow completion therapy . 7 . Is capable understand comply parameter outline protocol able sign inform consent , approve Independent Ethic Committee ( IEC ) /Institutional Review Board ( IRB ) prior initiation screen studyspecific procedure . Exclusion Criteria 1 . Has receive anticancer therapy include investigational agent , cytotoxic chemotherapy , radiation therapy biologic therapy within 21 day within period define 5 half life , whichever short , prior study drug administration . In addition subject recover less equal Grade 1 clinically significant adverse effects/toxicities previous therapy . 2 . Has undergone major surgery within 21 day Study Day 1 . 3 . Has untreated brain meningeal metastasis . Subjects treat brain metastasis radiographically clinically stable ( least 4 week therapy ) evidence cavitation hemorrhage brain lesion , eligible provide asymptomatic require corticosteroid ( must discontinue steroid least 1 week prior Study Day 1 ) . 4 . Has central thoracic tumor lesion define location involve abut hilar structure . The presence central nodal disease allow . 5 . Female subject pregnant breastfeeding . 6 . Has receive potential inhibitor metabolism linifanib within 21 day prior initial study drug administration . Such drug include CYP3A inhibitor e.g. , triazole , itraconazole , ketoconazole , fluconazole , grapefruit juice , verapamil , diltiazem , aprepitant , clarithromycin erythromycin ; CYP1A2 inhibitor e.g. , fluvoxamine , ciprofloxacin , mexiletine , propafenone zileuton ; CYP2C19 inhibitor e.g. , omeprazole ; CYP2C8 substrates e.g. , repaglinide , paclitaxel rosiglitazone CYP3A inducer e.g. , rifampin carbamazepine . 7 . Has proteinuria define National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) Grade &gt; 1 baseline measure urine dipstick ( 2+ great ) confirm 24 hour urine collection ( &gt; 1 g/24 hr ) . Subjects may rescreened proteinuria show control without intervention . 8 . Currently exhibit symptomatic persistent , uncontrolled hypertension define diastolic blood pressure ( BP ) &gt; 100 mmHg ; systolic blood pressure ( BP ) &gt; 150 mmHg . Subjects may rescreened BP show control without intervention . 9 . Clinically significant uncontrolled condition ( ) include limited : Active uncontrolled infection Class III IV heart failure define New York Heart Association functional classification system Unstable angina pectoris cardiac arrhythmia Myocardial infarction within last 6 month History adrenal insufficiency History cerebral vascular accident within last 6 month Active ulcerative colitis , Crohn 's disease , celiac disease condition interfere absorption History autoimmune disease kidney involvement History overt bleeding ( &gt; 30 mL bleeding/episode ) within 3 month study drug administration Psychiatric illness/social situation would limit compliance study requirement Any medical condition , opinion study investigator place subject unacceptably high risk toxicity 10 . Is receive combination antiretroviral therapy human immunodeficiency virus ( HIV ) . 11 . Has consume grapefruit grapefruit product within 21 day prior initial study drug administration . 12 . Has document leave ventricular ( LV ) ejection fraction &lt; 50 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>